US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

16.77

-0.5900-3.40%

Post-market: 16.770.00000.00%16:04 EDT

Volume:12.87K

Turnover:217.62K

Market Cap:5.67B

PE:187.40

High:17.19

Open:16.72

Low:16.31

Close:17.36

Loading ...

Overview Company News Filings

Telix CEO to Sell Shares for Personal Reasons

FDA Accepts Telix’s Kidney Cancer Imaging Agent for Priority Review

Telix Pharmaceuticals Obtains US FDA Priority Review for Cancer Imaging Agent

MT Newswires Live

Telix Pharmaceuticals Names New Board Chair

MT Newswires Live

Telix Pharmaceuticals Announces Board Renewal and Leadership Changes

FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review

Stock Track | Telix Soars 10% After Hours on Positive Trial Recruitment for Prostate Cancer Drug TLX591

Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami

Telix Pharmaceuticals Shifts Reporting Currency to US Dollars; Shares Hit All-Time High

MT Newswires Live

Telix Pharmaceuticals Shifts Reporting Currency to USD

Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Telix Pharmaceuticals Ltd. (OtherTLPPF), Repligen (RGEN) and Vertex Pharmaceuticals (VRTX)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Nanosonics Limited (OtherNNCSF) and Telix Pharmaceuticals Ltd. (OtherTLPPF)

UBS Sticks to Their Buy Rating for Telix Pharmaceuticals Ltd. (TLPPF)

Stock Track | Telix Pharmaceuticals Soars 9.88% on Outstanding FY2024 Results, Bolstered by Revenue Growth and Profitability

Stock Track | Telix Pharmaceuticals Soars 8.39% in Pre-Market After Impressive FY2024 Earnings

Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ...

Telix FY24 Total Revenue AU$783.2M, Up 56% From AU$502.5M YoY

Telix Pharmaceuticals Releases Corporate Governance Statement

Telix Pharmaceuticals Reports Record FY2024 Results and Sets Ambitious FY2025 Growth Targets

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TLX/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":16.77,"timestamp":1749240000000,"preClose":17.36,"halted":0,"volume":12873,"hourTrading":{"tag":"盘后","latestPrice":16.77,"preClose":16.77,"latestTime":"16:04 EDT","volume":34,"amount":578.18,"timestamp":1749240257024},"delay":0,"floatShares":275137421,"shares":338109048,"eps":0.089486,"marketStatus":"Market Closed","change":-0.59,"latestTime":"06-06 16:00:00 EDT","open":16.72,"high":17.1899,"low":16.31,"amount":217616.5022,"amplitude":0.050685,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.089486,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":17.36,"preHourTrading":{"tag":"盘前","latestPrice":17.03,"preClose":17.36,"latestTime":"09:28 EDT","volume":200,"amount":3406,"timestamp":1749216480030},"postHourTrading":{"tag":"盘后","latestPrice":16.77,"preClose":16.77,"latestTime":"16:04 EDT","volume":34,"amount":578.18,"timestamp":1749240257024},"volumeRatio":1.2461762087873647},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":275137421,"roa":"5.33%","roe":"13.92%","lyrEps":0.093266,"volumeRatio":1.2461762087873647,"shares":338109048,"dividePrice":0,"high":17.1899,"amplitude":0.050685,"preClose":17.36,"low":16.31,"week52Low":13.61,"pbRate":"15.33","psRate":"11.12","week52High":30.36,"institutionHeld":0,"latestPrice":16.77,"eps":0.089486,"divideRate":0,"volume":12873,"delay":0,"ttmEps":0.089486,"open":16.72,"prevYearClose":15.4,"prevWeekClose":16.9899,"prevMonthClose":16.9899,"prevQuarterClose":16.76,"fiveDayClose":16.9899,"twentyDayClose":17.05,"sixtyDayClose":17.16},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514040220","title":"Telix CEO to Sell Shares for Personal Reasons","url":"https://stock-news.laohu8.com/highlight/detail?id=2514040220","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514040220?lang=en_us&edition=fundamental","pubTime":"2025-02-26 15:40","pubTimestamp":1740555607,"startTime":"0","endTime":"0","summary":"An announcement from Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) is now available. Telix Pharmaceuticals announced that its CEO, Dr. Christian Behrenb...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-ceo-to-sell-shares-for-personal-reasons?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-ceo-to-sell-shares-for-personal-reasons?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2514076693","title":"FDA Accepts Telix’s Kidney Cancer Imaging Agent for Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2514076693","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514076693?lang=en_us&edition=fundamental","pubTime":"2025-02-26 11:17","pubTimestamp":1740539847,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) has shared an announcement. Telix Pharmaceuticals Limited announced that the FDA has accepted the Biologic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fda-accepts-telixs-kidney-cancer-imaging-agent-for-priority-review?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fda-accepts-telixs-kidney-cancer-imaging-agent-for-priority-review?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"2514073043","title":"Telix Pharmaceuticals Obtains US FDA Priority Review for Cancer Imaging Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2514073043","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514073043?lang=en_us&edition=fundamental","pubTime":"2025-02-26 10:57","pubTimestamp":1740538643,"startTime":"0","endTime":"0","summary":"The US Food and Drug Administration has accepted Telix Pharmaceuticals'  Biologics License Application for its investigational kidney cancer imaging agent TLX250-CDx, and granted a priority review that would pave the way for a commercial launch within the year, according to a Wednesday filing with the Australian bourse.The imaging agent has been given a Prescription Drug User Fee Act  date of Aug. 27. A PDUFA date provides an estimated timeline of when a decision on a drug application would be made.TLX250-CDx is said to be the first commercially available imaging agent to accurately and non-invasively diagnose and characterize clear cell renal cell carcinoma, a form of kidney cancer, per the filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","TLX","BK7067"],"gpt_icon":0},{"id":"2514209790","title":"Telix Pharmaceuticals Names New Board Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2514209790","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514209790?lang=en_us&edition=fundamental","pubTime":"2025-02-26 10:03","pubTimestamp":1740535405,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) said Kevin McCann will retire as its chairman on May 21, and Tiffany Olson will be the successor, according to a Wednesday Australian bourse filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TLX.AU","BK7067","TLX","XKO.AU","XJO.AU","XAO.AU"],"gpt_icon":0},{"id":"2514026685","title":"Telix Pharmaceuticals Announces Board Renewal and Leadership Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2514026685","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514026685?lang=en_us&edition=fundamental","pubTime":"2025-02-26 07:57","pubTimestamp":1740527875,"startTime":"0","endTime":"0","summary":"An announcement from Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) is now available. Telix Pharmaceuticals Limited has announced significant changes to ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-announces-board-renewal-and-leadership-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-announces-board-renewal-and-leadership-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2514026899","title":"FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2514026899","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514026899?lang=en_us&edition=fundamental","pubTime":"2025-02-26 07:51","pubTimestamp":1740527460,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Feb.  26, 2025  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3032511/0/en/FDA-Accepts-BLA-for-TLX250-CDx-Zircaix-for-Kidney-Cancer-Imaging-Grants-Priority-Review.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","BK4141","TLX","BK4543","BK4139","ASX"],"gpt_icon":0},{"id":"1100253250","title":"Stock Track | Telix Soars 10% After Hours on Positive Trial Recruitment for Prostate Cancer Drug TLX591","url":"https://stock-news.laohu8.com/highlight/detail?id=1100253250","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100253250?lang=en_us&edition=fundamental","pubTime":"2025-02-26 07:02","pubTimestamp":1740524549,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd.  saw its stock surge 10% in after-hours trading on Tuesday, following the announcement that a research center in Miami has begun recruiting and dosing patients for the company's Phase 3 clinical trial of TLX591, an investigational treatment for advanced prostate cancer.The ProstACT Global Phase 3 trial is evaluating TLX591, a radioantibody-drug conjugate  that targets prostate-specific membrane antigen , in combination with standard-of-care therapies for metastatic cas","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Telix Soars 10% After Hours on Positive Trial Recruitment for Prostate Cancer Drug TLX591","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX"],"gpt_icon":0},{"id":"2514095707","title":"Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami","url":"https://stock-news.laohu8.com/highlight/detail?id=2514095707","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514095707?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:30","pubTimestamp":1740486600,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Feb.  25, 2025  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) announces that the Biogenix Molecular Research Cent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3031912/0/en/Recruitment-Spotlight-Phase-3-Clinical-Trial-of-Novel-Prostate-Cancer-Radiopharmaceutical-Now-Active-in-Miami.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4233","BK4526","ASX","BK4139","BK4205","BK4213","BK4543","EEA","TGA","BK4144","DCP","TLX","BK4141","BK4528","UK"],"gpt_icon":0},{"id":"2514068089","title":"Telix Pharmaceuticals Shifts Reporting Currency to US Dollars; Shares Hit All-Time High","url":"https://stock-news.laohu8.com/highlight/detail?id=2514068089","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514068089?lang=en_us&edition=fundamental","pubTime":"2025-02-25 09:31","pubTimestamp":1740447116,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  will change its reporting currency to US dollars from Australian dollars, effective Jan. 1, according to a Tuesday Australian bourse filing.The change allows the company to align to the predominant currency used for reporting revenue, costs, and corresponding cash flows, which are primarily generated in the US, the filing added.The company will also convert the comparative periods in upcoming financial results to US dollars, per the filing.The company's shares fell almost 1% in recent Tuesday trade but earlier hit an all-time high.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","BK7067","TLX.AU","TLX","XKO.AU","XAO.AU"],"gpt_icon":0},{"id":"2514070035","title":"Telix Pharmaceuticals Shifts Reporting Currency to USD","url":"https://stock-news.laohu8.com/highlight/detail?id=2514070035","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514070035?lang=en_us&edition=fundamental","pubTime":"2025-02-25 07:09","pubTimestamp":1740438592,"startTime":"0","endTime":"0","summary":"An update from Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) is now available. Telix Pharmaceuticals Limited announced a change in its reporting currenc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-shifts-reporting-currency-to-usd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-shifts-reporting-currency-to-usd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX","USD"],"gpt_icon":0},{"id":"2514727027","title":"Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514727027","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514727027?lang=en_us&edition=fundamental","pubTime":"2025-02-25 01:00","pubTimestamp":1740416413,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Limited  could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 . This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for Telix Pharmaceuticals Limited basically reflects positivity about its earnings outlook that could translat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telix-pharmaceuticals-limited-tlx-upgraded-170013791.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TLX","TLX.AU"],"gpt_icon":0},{"id":"2513723396","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Telix Pharmaceuticals Ltd. (OtherTLPPF), Repligen (RGEN) and Vertex Pharmaceuticals (VRTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2513723396","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513723396?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:22","pubTimestamp":1740399737,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), Repligen (R...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-telix-pharmaceuticals-ltd-othertlppf-repligen-rgen-and-vertex-pharmaceuticals-vrtx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-telix-pharmaceuticals-ltd-othertlppf-repligen-rgen-and-vertex-pharmaceuticals-vrtx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","IE0002270589.USD","LU2362541513.USD","TLX","LU1093756168.USD","VRTX","LU2417539215.USD","IE00B19Z9Z06.USD","LU0823416689.USD","BK4137","IE0002141913.USD","LU0058720904.USD","BK4139","IE00B2B36J28.USD","IE0009355771.USD","LU2456880835.USD","LU1093756325.SGD","IE00B19Z3581.USD","LU2324357040.USD","HCSG","BK4533","LU0566484027.USD","LU1559883803.SGD","LU1585245621.USD","IE00BZ9MQY76.HKD","BK4567","LU0061475181.USD","LU1069344957.HKD","LU2236285917.USD","VERX","LU0320765992.SGD","IE00B894F039.SGD","RGEN","LU2362540622.SGD","LU0109394709.USD","BK4532","BK4588","LU0079474960.USD","LU0889565916.HKD","LU1815336091.USD","IE00B19Z3B42.SGD","IE00BJT1NW94.SGD","LU2362541273.HKD","BK4585","LU0757428866.USD","IE00BFTCPJ56.SGD","BK4023","LU1035775433.USD","LU1430594728.SGD","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2513762863","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Nanosonics Limited (OtherNNCSF) and Telix Pharmaceuticals Ltd. (OtherTLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2513762863","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513762863?lang=en_us&edition=fundamental","pubTime":"2025-02-24 08:40","pubTimestamp":1740357607,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nanosonics Limited (NNCSF – Research Report) and T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-nanosonics-limited-othernncsf-and-telix-pharmaceuticals-ltd-othertlppf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-nanosonics-limited-othernncsf-and-telix-pharmaceuticals-ltd-othertlppf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4137","HCSG","BK4139"],"gpt_icon":0},{"id":"2513457782","title":"UBS Sticks to Their Buy Rating for Telix Pharmaceuticals Ltd. (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2513457782","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513457782?lang=en_us&edition=fundamental","pubTime":"2025-02-23 13:07","pubTimestamp":1740287242,"startTime":"0","endTime":"0","summary":"UBS analyst Laura Sutcliffe maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report) today and set a price target of A$35.00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ubs-sticks-to-their-buy-rating-for-telix-pharmaceuticals-ltd-tlppf-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ubs-sticks-to-their-buy-rating-for-telix-pharmaceuticals-ltd-tlppf-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","TLPPF"],"gpt_icon":0},{"id":"1116083304","title":"Stock Track | Telix Pharmaceuticals Soars 9.88% on Outstanding FY2024 Results, Bolstered by Revenue Growth and Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=1116083304","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116083304?lang=en_us&edition=fundamental","pubTime":"2025-02-21 22:33","pubTimestamp":1740148418,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd.  witnessed a remarkable surge of 9.88% in its stock price during the pre-market trading session on Friday. This upward movement can be attributed to the company's stellar financial performance for the fiscal year 2024, as reported in its recent earnings call.Telix Pharmaceuticals demonstrated an impressive 56% year-over-year increase in revenue, surpassing its guidance. The company's adjusted EBITDA saw a substantial 70% improvement, reaching $99 million, reflecting it","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX"],"gpt_icon":0},{"id":"1176586263","title":"Stock Track | Telix Pharmaceuticals Soars 8.39% in Pre-Market After Impressive FY2024 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1176586263","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176586263?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:02","pubTimestamp":1740142944,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd.  witnessed an impressive 8.39% surge in its stock price during the pre-market trading session on Friday. This upward movement can be attributed to the company's stellar financial performance for the fiscal year 2024, as highlighted in its recent earnings call.The pharmaceutical company reported a remarkable 56% increase in revenue, surpassing its guidance. Additionally, Telix Pharmaceuticals demonstrated a substantial 70% improvement in adjusted EBITDA, reaching $99 mi","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Telix Pharmaceuticals Soars 8.39% in Pre-Market After Impressive FY2024 Earnings","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX"],"gpt_icon":0},{"id":"2513266351","title":"Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2513266351","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513266351?lang=en_us&edition=fundamental","pubTime":"2025-02-21 19:01","pubTimestamp":1740135675,"startTime":"0","endTime":"0","summary":"Revenue: Increased by 56% compared to the prior year.Adjusted EBITDA: Improved by 70% to $99 million.End of Year Cash Position: $710 million, bolstered by a convertible bond placement.R&D Investment: $195 million, focusing on regulatory filings and inventory scale-up.Precision Medicine Revenue Growth: 55% increase in sales of Aleix.Therapeutic Pipeline Investment: Increased by 74% to $82 million.Manufacturing Expansion: Incremental increase of $19 million in operating expenses due to acquisitions and facility expansion.2025 Revenue Guidance: Approximately $1.2 billion AUD or $770 to $800 million USD.GuruFocus has detected 8 Warning Signs with TLPPF.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Telix Pharmaceuticals Ltd  reported a 56% increase in revenue, surpassing guidance.Q: How does Telix Pharmaceuticals view the market growth for US PSMA sales in 2025?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telix-pharmaceuticals-ltd-tlppf-fy-110115381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["TLPPF","TLX.AU","TLX"],"gpt_icon":1},{"id":"2512449400","title":"Telix FY24 Total Revenue AU$783.2M, Up 56% From AU$502.5M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2512449400","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512449400?lang=en_us&edition=fundamental","pubTime":"2025-02-20 20:17","pubTimestamp":1740053853,"startTime":"0","endTime":"0","summary":"Telix FY24 Total Revenue AU$783.2M, Up 56% From AU$502.5M YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43844424/telix-fy24-total-revenue-au-783-2m-up-56-from-au-502-5m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX","TSS"],"gpt_icon":0},{"id":"2512418181","title":"Telix Pharmaceuticals Releases Corporate Governance Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2512418181","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512418181?lang=en_us&edition=fundamental","pubTime":"2025-02-20 16:17","pubTimestamp":1740039475,"startTime":"0","endTime":"0","summary":"The latest update is out from Telix Pharmaceuticals Ltd. ( ($AU:TLX) ). Telix Pharmaceuticals Ltd. has released its latest corporate governance sta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-releases-corporate-governance-statement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-releases-corporate-governance-statement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"2512989418","title":"Telix Pharmaceuticals Reports Record FY2024 Results and Sets Ambitious FY2025 Growth Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2512989418","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512989418?lang=en_us&edition=fundamental","pubTime":"2025-02-20 16:17","pubTimestamp":1740039444,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Telix Pharmaceuticals Ltd. ( ($AU:TLX) ). Telix Pharmaceuticals reported a record financial performance for FY2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-reports-record-fy2024-results-and-sets-ambitious-fy2025-growth-targets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-reports-record-fy2024-results-and-sets-ambitious-fy2025-growth-targets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":119,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1749182400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2025-06-06","current":173.121803,"percent":0.388489,"low":151.061716,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"high":205.576265,"avg":177.817132,"sd":12.490541,"marketCap":5638091901.1},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1}],"updateTime":1749438707634}}}